ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Labviva Announces Global Expansion, Appoints General Manager of Europe

BOSTON and LONDON , May 15, 2025 (GLOBE NEWSWIRE) -- Tariffs, trade barriers, and fragmented regulatory environments are disrupting the global supply chain and threatening the life sciences industry worldwide. That’s why Labviva, the leading AI procurement platform for life sciences, today announced its entry into Europe, establishing an international headquarters in London, and appointing life sciences veteran Dr. Carlo Iannicola as general manager. As part of the announcement, the company plans to accelerate global adoption of AI-enabled supply chain procurement while delivering a vast pool of diversified suppliers to Europe’s life sciences community.

Resolving a Fragmented Global Life Sciences Supply Chain
McKinsey reports that pharmaceutical procurement is inefficient and time-consuming, citing manual entries consume up to 30% of staff time, while life sciences suppliers struggle to digitize and integrate key data sources. It also recently identified augmented sourcing and realtime inventory optimization as powerful use cases capable of driving mass efficiencies in the sector. With the potential to reduce procurement management costs by up to 10% and increase productivity by up to 80%, AI in biopharmaceutical operations is a $7 billion annual business.

The “Amazonification” of Supply Chain Procurement
Labviva instantly connects research organizations with 90% of all life sciences manufacturers in the U.S. and Europe. This provides pharmaceutical, biopharmaceutical, and research institutions with direct access to a curated list of brand name, small, local, and green-certified businesses from around the world. With Labviva’s platform, scientists and procurement professionals can compare a diverse selection of products and pricing, based on their purchasing preferences, across multi-location research teams. This eliminates hours of manual research, reduces R&D costs, and ensures no-touch forecasting and inventory replenishment -- all while also ensuring regulatory compliance and sustainability.

“The global life sciences supply chain is ripe for transformation, and Labviva’s international expansion couldn’t have come at a better time. I’m delighted to announce the appointment of Carlo as our GM of Europe, where he will be responsible for bringing our proven AI procurement model to research organizations worldwide,” said Siamak Baharloo, CEO of Labviva. “Our goal is to help improve R&D for new pharmaceuticals by supporting the collaborative procurement efforts of the European Health Public Procurement Alliance and the EU Critical Medicines Act.”

Dr. Carlo Iannicola is an accomplished life sciences business development and operations executive, bringing extensive experience across molecular and human genetics research and business leadership across global markets. As GM of Europe, Iannicola is responsible for expanding Labviva’s global footprint and leading local customer success teams. He spent over 15 years at Roche Diagnostics, where he led the Oncology business across Europe, the Middle East, Africa, and Latin America. During his tenure there, Iannicola also helped scale operations for a fast-growing medical systems startup acquisition. Prior to this, he spent nearly a decade conducting advanced life sciences research at top U.S. research institutions including Stanford University and the University of California, San Francisco.

“I’ve witnessed how strategic expansion and strong organizational culture drive business success. I look forward to building a strong international team that will drive growth while nurturing our existing customer relationships,” said Dr. Carlo Iannicola, general manager of Europe. “The company’s innovative technology is what European life sciences organizations need to scale at the speed of science. I’m excited to help Labviva grow and continue to transform life sciences procurement worldwide.”

Labviva’s mission is to accelerate the pace of life science research by connecting suppliers, purchasing departments, and scientists through AI. With its new international headquarters in London’s prestigious life sciences hub in Kings Cross, located at 344-354 Gray's Inn Road London WC1X 8BP -- the company is poised to expand operations across Europe to address the in-market needs of its customers while helping research organizations address compliance, sustainability, and improve procurement operations worldwide. Many of the world’s leading pharmaceutical and educational research labs already trust and rely on Labviva to automate life science supply chain procurement.

About Labviva
Labviva connects researchers with suppliers of reagents, chemicals, consumables, and instrumentation in an intuitive, user-friendly platform that supports the priorities of scientists while staying compliant with purchasing rules. Suppliers can easily manage the content of their products, and products are mapped into scientific applications, techniques and protocols. To learn more about how Labviva accelerates the science of life, visit us at www.labviva.com.

Media Contacts:
Jennifer Schenberg
PenVine for Labviva
jennifer@penvine.com

Gabby Lescarbeau
PenVine for Labviva
gabby@penvine.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/cd63c11c-6bbf-474b-ab89-df4179cab918

https://www.globenewswire.com/NewsRoom/AttachmentNg/8d8eb1a2-1da9-48b1-9409-4356208cb7db


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.